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The mechanisms leading to viral persistence and hepatocarcinogenesis in hepatitis C virus (HCV) infection are not fully
understood. Recently, evidence has been accumulated that HCV viral proteins might interfere with gene expression of host
cells. Here, we demonstrate that the amino-terminal portion of HCV NS2 protein inhibits the expression of reporter genes
driven by different promoters or enhancer elements and also inhibits hepatitis B virus (HBV) gene expression and HBV DNArelevant for the pathogenesis of chronic HCV infection. ©
INTRODUCTION
Hepatitis C virus (HCV) infection leads to chronic liver
disease with the possible consequences of cirrhosis and
hepatocellular carcinoma (Bartenschlager and Lohmann,
2000; De Francesco, 1999; Heintges and Wands, 1997;
Shimotohno, 1995). The mechanisms leading to viral per-
sistence and hepatocarcinogenesis are not fully under-
stood. Recent evidence suggests that HCV viral proteins
could interfere with the gene expression of host cells. For
example, HCV core protein was shown to modify tran-
scription from a variety of promoter structures (Na-
ganuma et al., 2000; Ray et al., 1995, 1997, 1998), to alter
the activity of Rous sarcoma virus long terminal repeat
(LTR), simian virus (SV) 40 early promoters, and human
immunodeficiency virus type 1 (HIV-1) LTR and to inhibit
hepatitis B virus (HBV) and HIV replication (Ray et al.,
1997; Srinivas et al., 1996; Shih et al., 1993). Moreover, it
could be demonstrated that HCV NS4B protein activates
reporter constructs containing a variety of inducible cis-
enhancer elements (Kato et al., 2000) and that HCV NS5A
protein acts as a potent transcriptional activator and as
a modulator of cell-cycle regulatory genes and cell
growth (Chung et al., 1997; Ghosh et al., 1999; Kato et al.,
1997).
HCV NS2 protein is the first nonstructural protein en-
coded by the HCV genome and possesses the function
of an NS2/NS3 auto-protease (De Francesco, 1999; Ned-
dermann et al., 1997). The function depends on the pres-
ence of microsomal membranes and there is evidence© 2003 Elsevier Science (USA)
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that NS2 is a transmembrane protein (Grakoui et al.,
1993; Santolini et al., 1995). NS2 proteolytic activity is
abolished by mutations of amino acid residues 952 and
993 of the molecule (Grakoui et al., 1993; Hijikata et al.,
1993) and the catalytic activity is associated with the
carboxyl-terminal part of the molecule (Pallaoro et al.,
2001; Thibeault et al., 2001). In addition, it has been
shown that NS2 might also be important for the phos-
phorylation of NS5A (Liu et al., 1999). To date, an inter-
action of NS2 protein with host cells has not been de-
scribed. We have therefore investigated possible inter-
actions of NS2 with different hepatic and nonhepatic cell
lines using reporter gene and in vitro HBV replication
assays.
RESULTS AND DISCUSSION
We first investigated the effects of HCV NS2 on differ-
ent cellular and viral promoters in human hepatic and
nonhepatic cell lines using cotransfection experiments
with luciferase reporter constructs under the control of
cytomegalovirus (CMV) immediate-early promoter. The
expression of NS2 full-length and amino-terminal trun-
cated constructs was determined by Western blot (Fig.
1). Cotransfection of HepG2 cells with NS2 expression
plasmids resulted in a specific and highly reproducible
70–80% reduction in luciferase activity which was not
observed after cotransfection with HCV plasmids encod-
ing Core, E1, or p7, respectively (Fig. 2A). The inhibitory
effect of HCV NS2 on luciferase expression was dose-
dependent (Fig. 2B). Moreover, cotransfection with the
NS2 expression vector resulted—with some variabil-replication. The inhibitory effect of HCV NS2 on liver and
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human hepatoma cell line Huh7 as well as in the non-non-li
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hepatic cell lines HeLa (cervix carcinoma), Jurkat (lym-
phoma), and NIH 3T3 (murine fibroblasts; Fig. 2C).
We next investigated the influence of HCV NS2 on
other cellular and viral promoters. In these experiments,
reporter constructs encoding luciferase under the control
of different promoter/enhancer structures were cotrans-
fected with the full-length NS2 construct (pCMVLIC-
NS2/AA 810-1026) or empty vector control. As shown in
Fig. 2D, NS2 inhibited luciferase expression under the
control of the human full-length tumor necrosis factor
(TNF) alpha promoter and a minimal TNF alpha promoter
lacking NFkappaB sites, as well as under control of
heterologous SV40 promoter/enhancer sequences,
NFkappaB binding sites, and the human ferrochelatase
promoter, which is devoid of general cis-elements such
as TATA or CAAT boxes (Magness et al., 1998).
To rule out cytotoxic effects, HeLa tet-off cells were
transfected with plasmid-encoding NS2 (or NS2 anti-
sense as a control) and enhanced green fluorescent
protein (EGFP) from a bidirectional, tetracycline-respon-
sive promoter. Expression of the construct was induced
by withdrawal of tetracycline for 48 h after transfection
and the expression of NS2 and EGFP was analyzed by
indirect immunofluorescence or direct fluorescence mi-
croscopy, respectively (Fig. 3). Transfection with a control
vector showed a strong EGFP expression (Fig. 3A). In
contrast, EGFP fluorescence was suppressed to very low
levels (Fig. 3B) after transfection with the bidirectional
HCV NS2/EGFP expression construct. In addition, we did
not observe any signs of cytotoxicity using lactate dehy-
drogenase (LDH) assays for HepG2 or HeLa tet-off cells
48 h after transient transfection with NS2 expression
constructs (Fig. 4).
Considering the broad inhibitory effect of NS2 on dif-
ferent reporter gene constructs, we further investigated
whether HCV NS2 sequences might also interfere with
HBV gene expression and replication. For these experi-
ments, Huh7 cells were cotransfected with HBV DNA
(dimer) (Tong et al., 1990) and different HCV NS2 or
control constructs. Interestingly, expression of full-length
NS2 significantly reduced the secretion of HBV surface
antigen (HBsAg) and e antigen (HBeAg) in the culture
supernatant. HBV DNA replication, which is dependent
on transcription of pregenomic RNA by the core pro-
moter, was also moderately inhibited (Figs. 5A and 5B).
Finally, to better understand the structural basis of
NS2-mediated inhibition of gene expression and to rule
out unwanted effects due to the expression of NS2 as
single viral protein, several expression constructs con-
taining different parts of HCV NS2 in the molecular con-
text of adjacent regions (E2-p7) were cloned. Again,
these plasmids were cotransfected with the pCMVLIC-
LUC reporter plasmid into the hepatic cell lines HepG2
or Huh7. While all constructs containing the amino-ter-
minal portion of the HCV NS2 sequence (amino acids
810–940) resulted in a significant decrease in luciferase
activity, this effect was not observed for constructs con-
taining sequences from the carboxyl-terminal part of the
NS2 (Fig. 6).
Taken together, the data suggest a broad inhibitory
effect of HCV NS2 protein. The effect could be de-
tected—with some variability—in cell lines of different
origin. This variability might be due to the differences in
transfection efficiency. Alternatively, the variability might
reflect a cell-specific susceptibility for the inhibitory ef-
fect of NS2. Moreover, the inhibitory effect was observed
for a variety of cellular and viral promoters, including
inhibition of in vitro HBV replication and gene expression
from HBV liver-specific (core) and non-liver-specific (S)
promoters. Thus, the effect could be detected using
structurally different promoter or enhancer structures,
including heterologous (CMV immediate early, SV-40)
and “conventional” promoters (human TNF alpha) as well
as minimal promoters/response elements (minimal TNF
alpha promoter, NFkappa B binding sites) and promoter
structures devoid of general cis-elements such as TATA
and CAAT boxes (ferrochelatase promoter). Several find-
ings demonstrate that this broad inhibitory effect of NS2
is nevertheless specific: First, inhibition was dose-de-
pendent and could be observed only with expression of
NS2 but not with expression of other HCV structural
proteins. Second, transient expression of NS2 did not
result in cytotoxic effects. Third, the effect could be
reproduced in different experimental systems such as
reporter-gene assays or HBV replication in a permissive
cell line. Fourth, the inhibition of reporter-gene expres-
sion or HBV replication was also observed when NS2
FIG. 1. Expression of HCV NS 2 sequences in human hepatoma cells.
Human Huh7 hepatoma cells were transfected with different expres-
sion vectors and cell lysates were prepared 48 h posttransfection for
Western blots. NS2 expression was detected with rabbit polyclonal
antiserum against NS2. Lane 1: pCMVLIC-NS2/amino acids (AA) 827-
1026/STOP 828; Lane 2: empty vector pCMVLIC; Lane 3: GFP transfec-
tion control construct (pGreenlantern; Life Technologies; Eggenstein,
Germany); Lane 4: pCMVLIC-NS2 AA 810-1026 (full-length NS2); Lane 5
pCMVLIC-NS2/AA827–1026 (N-terminal truncation).
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protein was expressed in the context of adjacent pro-
teins. Fifth, the effect was specifically associated with
expression of the amino-terminal part of NS2 protein.
The observed inhibition of cellular and viral promoters
represents a hitherto unknown activity of NS2 protein
due to a yet unknown mechanism. Mapping experiments
narrowed down the inhibitory sequence to the amino-
terminal portion (AA 810–940) of NS2 protein. Since the
NS2/NS3 auto-protease activity is mediated by the car-
boxyl-terminus of NS2 (Grakoui et al., 1993; Pallaoro et
al., 2001; Thibeault et al., 2001), it is unlikely that the
inhibitory effect is caused by NS2 proteolytic activity.
An alternative mechanism might be the interference of
HCV NS2 protein with transcription, in particular with a
general transcription factor and/or translation (e.g., by
protein–protein or protein–RNA/DNA interactions).
This could explain the relatively broad inhibitory effect
of NS2.
With regard to possible functional consequences, the
inhibition of HBV in vitro replication and secretion of HVB
viral proteins by HCV NS2 is similar to the effect de-
scribed for HCV core protein and could contribute to the
low HBV replication status observed in some patients
with HBV/HCV coinfection (Lee et al., 1997; Sagnelli et
al., 2001). In addition, modification of cellular gene ex-
pression by HCV NS2 could importantly contribute to the
pathogenesis of chronic hepatitis C and HCV-associated
hepatocarcinogenesis.
FIG. 2. 2A HCV NS2 inhibits CMV immediate early promoter. HepG2 cells were cotransfected with different HCV expression vectors and a
CMV-driven luciferase reporter plasmid. Cotransfection with an HCV NS2 expression vector decreased luciferase activity by 70–80% relative to vector
control, while no significant reduction was observed after cotransfection with other expression constructs encoding for HCV core, E1, or p7 protein.
(B) The inhibitory effect of HCV NS2 is dose-dependent. HepG2 cells were cotransfected with constant amounts of luciferase reporter construct and
increasing amounts of NS2 expression plasmid adding empty vector to keep the total amount of transfected DNA constant in all transfections. (C)
The inhibitory effect of HCV NS2 in non-hepatic cell lines. Huh 7 (human hepatoma), HeLa (human cervix carcinoma), Jurkat (human lymphoma), and
NIH 3T3 cells (murine fibroblasts) were cotransfected with equal amounts of CMV-driven luciferase reporter plasmid and pCMVLIC-NS2/AA810–1026
(open bars) or empty vector control (filled bars). Cotransfection with the NS2 expression vector resulted in significantly decreased reporter gene
activity with some variability in cell lines of different origin. (D) HCV NS2 inhibits multiple cellular and viral promoters/enhancers. The effect of HCV
NS2 luciferase reporter-gene constructs under the control of different structural promoter or enhancer elements was assessed in HepG2 cells. HCV
NS2 sequences inhibited reporter-gene expression to varying extents from human ferrochelatase promoter, an NFkappa B-luciferase construct, a
full-length and a minimal human TNF alpha promoter without NFkappa B binding sites, and two viral promoters (SV-40 and CMV immediate early
promoter). All data in this figure are given as mean  standard deviation of luciferase activity relative to vector control determined 48 h after
transfection.
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MATERIALS AND METHODS
Plasmids
HCV-H strain sequences were PCR-amplified from a
plasmid (Inchauspe et al., 1991) and cloned into the
expression vectors pCMVLIC (Pharmingen, Hamburg,
Germany), pcDNA 3.1() (Invitrogen, San Diego, CA), and
pBiEGFP (Clontech, Heidelberg, Germany) as previously
described (Dumoulin et al., 1999). A Kozak consensus
sequence was included for optimal translation efficiency
(Kozak, 1986). The resulting vectors were pCMVLIC-
Core/amino acids (AA) 1–191, -E1/AA 192–383, -p7/AA
747–809, -NS2/AA 810-1026. The pcDNA 3.1.-based vec-
tors were designated pcDNA3.1-NS2/AA 810-1026, -NS2-
delN/AA 827-1026, -NS2-STOP/AA 827-1026 with a pre-
mature stop codon at position 828. For expression of
EGFP and NS2 from a bidirectional vector, HCV se-
quences were cloned into pBi-EGFP either in sense or in
antisense orientation.
In addition, a panel of luciferase reporter constructs
under control of different promoter/enhancers was used
in this study: human ferrochelatase promoter (pHFc-Luc;
FIG. 3. HCV NS2 inhibits EGFP expression from a bidirectional plasmid in HeLa tet-off cells. HeLa tet-off cells were transiently transfected with the
bidirectional expression vector pBiEGFP-NS2/AA 810-1026 encoding full-length NS2 (B and D) and a control plasmid containing NS2 sequences in
an antisense orientation (A and C). Expression from tetracycline-responsive promoter was induced by culture of the cells in the absence of
tetracycline for 48 h. Cells were then processed for NS2-immunofluoresence and EGFP fluorescence. Transfection with antisense control showed
bright EGFP fluorescence (A), while these cells displayed no specific NS2 immunoreactivity (C). In contrast, only background EGFP immunofluores-
cence could be detected in cells transfected with the NS2 full-length construct (B and D; magnification, 400).
FIG. 4. Transient expression of HCV NS2 is not cytotoxic. HepG2 or
HeLa tet-off cells were transiently transfected with pCMVLIC-Core,
pCMVLIC NS2/AA 810-1026, and vector control (HepG2) or pBiEGFP-
Core, pBiEGFP-NS2/AA 810-1026, or pBiEGFP-NS2 antisense control
(HeLa tet-off) and expression from tetracycline-responsive promoter
was induced as described above. The regular 10% FCS medium was
replaced by 2% FCS medium 16 h after transfection and LDH activity
was determined from the supernatant 48 h after transfection using a
commercially available cytotoxicity detection kit (Roche Molecular Di-
agnostics, Mannheim, Germany).
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a gift from David A. Brenner, University of North Carolina,
Chapel Hill, NC (Magness et al., 1998)), nuclear factor
(NF) kappaB (pNFkappaB-Luc containing 5 NFkappaB
elements; Stratagene, Heidelberg, Germany), human tu-
mor necrosis factor (TNF)-alpha full-length promoter
and human TNF-alpha promoter with a deletion of its
NFkappaB sites (nucleotides 1–1141 and nucleotides
938-1141; GenBank Accession No. L11698; kindly pro-
vided by Joachim Fandrey and Stilla Frede; University of
Essen, Germany), simian virus 40 promoter/enhancer
(pGL2; Promega, Heidelberg, Germany), and cytomega-
lovirus immediate early promoter (pCMVLIC-LUC;
Pharmingen). Finally, the following constructs encom-
passing different parts of HCV NS2 and adjacent se-
quences were cloned: pCMVLIC-NS2/AA 940-1026,
-NS2/AA 900-1026, -NS2/AA 810–940, -NS2/AA 810–900,
E2-p7-NS2/AA 730-1006.
Cell lines and transfections
HepG2 (human hepatoma), Jurkat (human CD4 Lym-
phoma), and HeLa (human cervix carcinoma) cells were
purchased from DSMZ (Braunschweig, Germany); Huh 7
(human hepatoma) and NIH 3T3 (murine fibroblasts)
cells were obtained from ATCC (Rockville, MD). HeLa
tet-off cells stably expressing the tetracycline transacti-
vator protein were acquired from Clontech. Cells were
cultured in a humidified 37°C/5% CO2 atmosphere in
RPMI 1640 with glutamax (Life Technologies, Eggen-
stein, Germany) supplemented with 10% fetal calf serum
(Biochrom, Berlin, Germany), except for Huh 7 cells,
which were cultured in minimal essential medium, 2 mM
L-glutamine, nonessential amino acids, and 10% fetal calf
serum (all chemicals from Sigma, St. Louis, MO). HepG2,
Jurkat, HeLa, and NIH3T3 cells were transfected for 16 h
FIG. 5. HCV NS2 inhibits HBV DNA replication and production of HBsAg and HBeAg. Huh7 cells were cotransfected with HBV and either vector
control, an HCV NS2 full-length expression vector, an HCV NS2 construct with a stop mutation immediately downstream the Kozak sequence, or an
N-terminal truncated NS2 variant. HBV DNA replication was monitored at Day 5 after transfection (A); HBsAg and HBeAg secretion were detected by
enzyme immunoassay or radioimmunoassay, respectively (B).
FIG. 6. The amino-terminal portion of HCV NS2 mediates the inhib-
itory effect. Expression vectors were constructed encompassing differ-
ent parts of HCV NS2 and adjacent regions in pCMVLIC. Cotransfection
of HepG2 cells was carried out as described for Fig. 2A. The inhibitory
effect on luciferase activity was observed only after cotransfection with
sequences which included the amino-terminal portion of NS2 (amino
acids 810-1026, 810–940, 730-1006).
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with DMRIE-C reagent (Life Technologies) at a 1:4 (g
DNA/l DMRIE-C) molar ratio; Huh7 cells were trans-
fected for 6 h using Mirus TransIT-LT1 (Panvera, Madi-
son, WI) at a 1:3 (g DNA/l Mirus reagent) molar ratio.
All cell lines were grown in 24-well plates to 50–70%
confluency at the time of transfection; unless stated
otherwise, 1:1 molar ratios of different plasmids were
used for cotransfection assays.
Immunoblot
To verify expression from vector constructs, lysates
were prepared from washed cells in hot Laemmli buffer
(Laemmli, 1970) 48 h after transfection. Lysates were
separated by 15% sodium dodecyl sulfate–polyacrylam-
ide gel electrophoresis (SDS-PAGE) and blotted (Poly-
screen membrane; NEN, Boston, MA). The blots were
blocked with 5% nonfat milk at room temperature for 30
min and NS2 immunoreactivity was detected by chemi-
luminescence (SuperSignal West Pico; Pierce, Rockford,
IL) after overnight incubation with a 1:5000 dilution of
rabbit polyclonal antiserum against NS2 (WU 107, gener-
ously provided by Charles Rice, Rockefeller University,
New York, NY) (Grakoui et al., 1993; Fig. 1).
Luciferase assays
For luciferase assays, cells were lysed 48 h after
cotransfection and luciferase activity was determined
according to the manufacturer’s instructions (luciferase
assay kit; Promega) using a Berthold Autolumat lumi-
nometer (Berthold, Bergisch Gladbach, Germany). Lucif-
erase determinations were done in triplicate wells and
results of cotransfection experiments are given as
mean  standard deviation of luciferase activity relative
to vector control. At least three independent sets of
experiments were performed with similar results.
Immunofluorescence
HeLa tet-off cells were grown on a coverslip, tran-
siently transfected with pBi-EGFP-NS2/AA 810-1026 or a
control construct containing NS2 sequence in an anti-
sense orientation and fixed for 20 min at room temper-
ature in 4% paraformaldehyde (Sigma, Deisenhofen, Ger-
many). Cells were permeabilized for 10 min at room
temperature with 0.01% Triton X-100 in phosphate-buff-
ered saline (Sigma) and incubated overnight at 4°C with
the rabbit polyclonal NS2 antiserum WU-107 at a 1:500
dilution. Bound antibody was detected with rhodamine-
labeled goat anti-rabbit antibody (Dako, Hamburg, Ger-
many; 1:1000) and viewed with a Leitz fluorescence mi-
croscope (Leitz, Wetzlar, Germany).
Cytotoxicity assay
For the assessment of possible cytotoxic effects of
HCV NS2 expression, cell supernatants were analyzed
48 h after transfection for LDH activity using the cytotox-
icity detection kit (Roche Molecular Diagnostics, Mann-
heim, Germany). To avoid background LDH activity, cells
were grown in 2% FCS after transfection. LDH release
was determined from 100 l supernatant and absor-
bance was measured at 480 nm using a reference wave-
length at 620 nm.
HBV DNA replication and production of HbsAg and
HBeAg
Huh7 cells were cultured overnight to a density of
50–70% and cotransfected with HBV DNA (dimer) (Tong
et al., 1990) together with either vector control, HCV NS2
full-length expression vector (pcDNA3.1.-NS2/AA810-
1026; NS2), HCV NS2 construct with a stop mutation
immediately downstream the Kozak sequence (pcDNA3.1.-
NS2/AA827-1026-828TAG; NS2-Stop), or an N-terminal
truncated NS2 variant (pcDNA3.1.-NS2/AA940-1026; NS2-
delN). HBV DNA replication was monitored at day 5 after
transfection by Southern blot hybridization using HBV
DNA as a probe (Tong et al., 1990). HBsAg secretion was
detected by enzyme immunoassay (Auszyme monoclo-
nal; Abbott Laboratories, Abbott Park, IL), HBeAg secre-
tion by a radioimmunoassay (125I RIA Kit; DiaSorin, Still-
water, MN) according to the manufacturer’s instructions
at 3 and 5 days after transfection.
Statistics
Statistical analysis using Student’s t tests was per-
formed with Microsoft Excel 97 (Microsoft Corp., Red-
mond, WA).
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